On September 25, council of the Federal Trade Commission (FTC) in addition to the Department of Justice's Antitrust Division testified before the House Judiciary Committee's Antitrust Task Force concerning their antitrust enforcement behavior.

Deborah Platt Majoras, chairperson of the FTC, testified on the subject of the commission's labors to examine and confront agreements in the middle of pharmaceutical companies and physicians that leave without consumers of lower prices and higher quality. She also dyed examples of mergers and other actions that decrease rivalry surrounded by medical device manufacturers, hospitals, and clinics.

While discussing pharmaceutical issues, Majoras had spoken anxiety concerning anticompetitive agreements that boundary consumer right of entry to general drugs. She referred in particular to convinced agreements, recognized as "keeping out payment settlements," underneath which a brand-name drug producer pays a possible generic player to dump its confront and holdup toward the inside the market. Recitation these settlements as "one of the greatest threats American consumers face today," Majoras expressed support for a legislative solution to prohibit such settlements, while allowing exceptions for agreements that do not harm competition.